Prospective Grant of Exclusive License: Development of In Vitro Diagnostics for the Detection of Diseases or Pathogenic Agents, 8082-8083 [2016-03187]

Download as PDF 8082 Federal Register / Vol. 81, No. 31 / Wednesday, February 17, 2016 / Notices (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: February 10, 2016. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–03121 Filed 2–16–16; 8:45 am] BILLING CODE 4140–01–P Dated: February 10, 2016. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2016–03124 Filed 2–16–16; 8:45 am] National Institutes of Health BILLING CODE 4140–01–P National Cancer Institute; Notice of Closed Meetings asabaliauskas on DSK5VPTVN1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; Omnibus SEP–12. Date: March 15, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Residence Inn Bethesda, Downtown, 7335 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Timothy C. Meeker, MD, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W624, Rockville, MD 20850, 240– 276–6464 meekert@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Planning Grants for Global Research Infrastructure in Non-Communicable Disease. Date: April 27–28, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Marriott Courtyard Gaithersburg Washingtonian Center, 204 Boardwalk Place, Gaithersburg, MD 20878. Contact Person: Michael B. Small, Ph.D., Chief, Program & Review Extramural Staff Training Office, Division of Extramural Activities, National Cancer Institute, NIH, VerDate Sep<11>2014 19:05 Feb 16, 2016 Jkt 238001 9609 Medical Center Drive, Room 7W412, Bethesda, MD 20892–9750, 240–276–6438 smallm@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Development of In Vitro Diagnostics for the Detection of Diseases or Pathogenic Agents National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), at the National Institutes of Health, Department of Health and Human Services, is contemplating the grant to Altra Tech, Ltd. (‘‘AltraTech’’), a company incorporated under the laws of the Ireland, having an office in Shannon, Ireland, an exclusive patent commercialization license to practice the following inventions embodied in the following patent applications: US Provisional Patent Application No.60/ 846,354, entitled, ‘‘(S,S)-trans-1,2cyclopentane Diamine-modified and Gamma-lysine-modified Peptide Nucleic Acids as Probes for Nucleic Acid Detection: Synthesis and Applications,’’ filed 22 Sep 2006 [HHS Ref No. E–308–2006/0–US–01]; US Provisional Patent Application No. 60/ 896,667, entitled, ‘‘Synthesis of Transtert-butyl-2aminocyclopentylcarbamate,’’ filed 23 Mar 2007 [HHS Ref No. E–308–2006/1– US–01]; International Application PCT/ US2007/020466, entitled, ‘‘Synthesis of Trans-tert-butyl-2aminocyclopentylcarbamate,’’ filed 21 Sep 2007 [HHS Ref No. E–308–2006/2– SUMMARY: PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 PCT–01]; US Patent Application No. 12/ 441,925, filed 21 Sep 2007, [HHS Ref No. E–308–2006/2–US–02]; US Patent Application No. 12/409,159, entitled, ‘‘Cross-Coupled Peptide Nucleic Acids for Detection of Nucleic Acids of Pathogens,’’ filed 23 Mar 2009 [HHS Ref No. E–308–2006/3–US–01]; US Patent No. 9,156,778, entitled, ‘‘Cross-Coupled Peptide Nucleic Acids for Detection of Nucleic Acids of Pathogens,’’ issued 13 Oct 2015 [HHS Ref No. E–308–2006/3– US–02]; US Provisional Patent Application No. 61/684,354, entitled, Cyclopentane-peptide Nucleic Acids for Qualitative and Quantitative Detection of Nucleic Acids,’’ filed 17 Aug 2012 [HHS Ref No. E–260–2012/0–US–01]; International Application PCT/US2013/ 055252, filed 16 Aug 2013 [HHS Ref No. E–260–2012/0–PCT–02]; European Patent Application No. 13753962.3, filed 11 Feb 2015, [HHS Ref No E–260– 2012/0–EP–03]; Korea Patent Application No. 10–2015–7006286, filed 11 Mar 2015, [HHS Ref No E–260–2012/ 0–KR–04]; US Patent Application No. 14/421,732, filed 13 Feb 2015, [HHS Ref No E–260–2012/0–US–05]; US Provisional Patent Application No. 61/ 333,442, filed 11 May 2010, [HHS Ref No E–129–2010/0–US–01]; International Patent Application No. PCT/US2011/ 036090, filed 11 May 2011, [HHS Ref No. E–129–2010/0–PCT–02]; European Patent Application No. 11721899.0, filed 11 May 2011, [HHS Ref No. E–129– 2010/0–EP–03]; and US Patent Application No. 13/697,123, filed 9 Nov 2012, [HHS Ref No. E–129–2010/0–US– 04]. The patent rights in these inventions have been assigned to the United States of America. AltraTech is seeking a worldwide territory for this license. The field of use may be limited to exclusive use of the licensed patent rights limited to the development and sale of transcyclopentane-modified peptide nucleic acids (PNA) in a diagnostic test system incorporating AltraTech’s proprietary sample preparation and AltraTech’s proprietary semiconductor sensor technology for the detection of infectious diseases or pathogenic agents including viruses and microorganisms. DATES: Only written comments or applications for a license (or both) which are received by the Technology Advancement Office, NIDDK, on or before March 3, 2016 will be considered. ADDRESSES: Requests for copies of the patent application, patents, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Patrick McCue, Ph.D., Senior Licensing and Patenting E:\FR\FM\17FEN1.SGM 17FEN1 Federal Register / Vol. 81, No. 31 / Wednesday, February 17, 2016 / Notices Manager, Technology Advancement Office, The National Institutes of Diabetes and Digestive and Kidney Diseases, 12A South Drive, Bethesda, MD 20892, Telephone: (301) 451–5560; Email: patrick.mccue@nih.gov. A signed confidentiality non-disclosure agreement will be required to receive copies of any patent applications that have not been published by the United States Patent and Trademark Office or the World Intellectual Property Organization. SUPPLEMENTARY INFORMATION: These technologies, and the corresponding patent applications, are directed to cyclopentane-peptide nucleic acids (PNA) and their use in qualitative and quantitative detection of nucleic acids. The technologies overcome a stability problem and sensitivity to outside contamination that is inherent to PCRbased detection systems, wherein the PNA probes bind to DNA with greater stability and selectivity compared to a complementary DNA sequence. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the Technology Advancement Office, NIDDK, receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. Properly filed competing applications for a license in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: February 10, 2016. Anna Amar, Acting Deputy Director, Technology Advancement Office, NIDDK. [FR Doc. 2016–03187 Filed 2–16–16; 8:45 am] BILLING CODE 4140–01–P asabaliauskas on DSK5VPTVN1PROD with NOTICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. 19:05 Feb 16, 2016 Jkt 238001 Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Collaborative Projects in Organ Fibrosis. Date: March 8, 2016. Time: 8:30 a.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: Courtyard by Marriott, 5520 Wisconsin Avenue, Chevy Chase, MD 20815. Contact Person: Kristen Page, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7185, Bethesda, MD 20892, 301–435–0725, kristen.page@nih.gov. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Small Business Point of Care. Date: March 9, 2016. Time: 9:00 a.m. to 11:00 a.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817. Contact Person: Kristin Goltry, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7198, Bethesda, MD 20892, 301–435–0297, goltrykl@mail.nih.gov. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Small Business Point of Care. Date: March 9–10, 2016. Time: 11:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817. Contact Person: Kristin Goltry, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7198, Bethesda, MD 20892, 301–435–0297, goltrykl@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) DEPARTMENT OF HEALTH AND HUMAN SERVICES VerDate Sep<11>2014 The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Dated: February 10, 2016. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–03122 Filed 2–16–16; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 8083 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel, PAR–14– 166: Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01). Date: February 29, 2016. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: David L Williams, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5110, MSC 7854, Bethesda, MD 20892, (301) 435– 1174, williamsdl2@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, Topics in Bacterial Pathogenesis. Date: March 9, 2016. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Richard G Kostriken, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3192, MSC 7808, Bethesda, MD 20892, 240–519– 7808, kostrikr@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Digestive Sciences. Date: March 9, 2016. Time: 8:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: Cambria Hotel & Suites, 1 Helen Heneghan Way, Rockville, MD 20850. Contact Person: Martha Garcia, Ph.D., Scientific Reviewer Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2186, MSC 7818, Bethesda, MD 20892, 301–435– 1243, garciamc@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; E:\FR\FM\17FEN1.SGM 17FEN1

Agencies

[Federal Register Volume 81, Number 31 (Wednesday, February 17, 2016)]
[Notices]
[Pages 8082-8083]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-03187]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Development of In Vitro 
Diagnostics for the Detection of Diseases or Pathogenic Agents

AGENCY: National Institute of Diabetes and Digestive and Kidney 
Diseases, National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 
part 404.7(a)(1)(i), that the National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK), at the National Institutes of 
Health, Department of Health and Human Services, is contemplating the 
grant to Altra Tech, Ltd. (``AltraTech''), a company incorporated under 
the laws of the Ireland, having an office in Shannon, Ireland, an 
exclusive patent commercialization license to practice the following 
inventions embodied in the following patent applications: US 
Provisional Patent Application No.60/846,354, entitled, ``(S,S)-trans-
1,2-cyclopentane Diamine-modified and Gamma-lysine-modified Peptide 
Nucleic Acids as Probes for Nucleic Acid Detection: Synthesis and 
Applications,'' filed 22 Sep 2006 [HHS Ref No. E-308-2006/0-US-01]; US 
Provisional Patent Application No. 60/896,667, entitled, ``Synthesis of 
Trans-tert-butyl-2-aminocyclopentylcarbamate,'' filed 23 Mar 2007 [HHS 
Ref No. E-308-2006/1-US-01]; International Application PCT/US2007/
020466, entitled, ``Synthesis of Trans-tert-butyl-2-
aminocyclopentylcarbamate,'' filed 21 Sep 2007 [HHS Ref No. E-308-2006/
2-PCT-01]; US Patent Application No. 12/441,925, filed 21 Sep 2007, 
[HHS Ref No. E-308-2006/2-US-02]; US Patent Application No. 12/409,159, 
entitled, ``Cross-Coupled Peptide Nucleic Acids for Detection of 
Nucleic Acids of Pathogens,'' filed 23 Mar 2009 [HHS Ref No. E-308-
2006/3-US-01]; US Patent No. 9,156,778, entitled, ``Cross-Coupled 
Peptide Nucleic Acids for Detection of Nucleic Acids of Pathogens,'' 
issued 13 Oct 2015 [HHS Ref No. E-308-2006/3-US-02]; US Provisional 
Patent Application No. 61/684,354, entitled, Cyclopentane-peptide 
Nucleic Acids for Qualitative and Quantitative Detection of Nucleic 
Acids,'' filed 17 Aug 2012 [HHS Ref No. E-260-2012/0-US-01]; 
International Application PCT/US2013/055252, filed 16 Aug 2013 [HHS Ref 
No. E-260-2012/0-PCT-02]; European Patent Application No. 13753962.3, 
filed 11 Feb 2015, [HHS Ref No E-260-2012/0-EP-03]; Korea Patent 
Application No. 10-2015-7006286, filed 11 Mar 2015, [HHS Ref No E-260-
2012/0-KR-04]; US Patent Application No. 14/421,732, filed 13 Feb 2015, 
[HHS Ref No E-260-2012/0-US-05]; US Provisional Patent Application No. 
61/333,442, filed 11 May 2010, [HHS Ref No E-129-2010/0-US-01]; 
International Patent Application No. PCT/US2011/036090, filed 11 May 
2011, [HHS Ref No. E-129-2010/0-PCT-02]; European Patent Application 
No. 11721899.0, filed 11 May 2011, [HHS Ref No. E-129-2010/0-EP-03]; 
and US Patent Application No. 13/697,123, filed 9 Nov 2012, [HHS Ref 
No. E-129-2010/0-US-04].
    The patent rights in these inventions have been assigned to the 
United States of America. AltraTech is seeking a worldwide territory 
for this license. The field of use may be limited to exclusive use of 
the licensed patent rights limited to the development and sale of 
trans-cyclopentane-modified peptide nucleic acids (PNA) in a diagnostic 
test system incorporating AltraTech's proprietary sample preparation 
and AltraTech's proprietary semiconductor sensor technology for the 
detection of infectious diseases or pathogenic agents including viruses 
and microorganisms.

DATES: Only written comments or applications for a license (or both) 
which are received by the Technology Advancement Office, NIDDK, on or 
before March 3, 2016 will be considered.

ADDRESSES: Requests for copies of the patent application, patents, 
inquiries, comments, and other materials relating to the contemplated 
exclusive license should be directed to: Patrick McCue, Ph.D., Senior 
Licensing and Patenting

[[Page 8083]]

Manager, Technology Advancement Office, The National Institutes of 
Diabetes and Digestive and Kidney Diseases, 12A South Drive, Bethesda, 
MD 20892, Telephone: (301) 451-5560; Email: patrick.mccue@nih.gov. A 
signed confidentiality non-disclosure agreement will be required to 
receive copies of any patent applications that have not been published 
by the United States Patent and Trademark Office or the World 
Intellectual Property Organization.

SUPPLEMENTARY INFORMATION: These technologies, and the corresponding 
patent applications, are directed to cyclopentane-peptide nucleic acids 
(PNA) and their use in qualitative and quantitative detection of 
nucleic acids. The technologies overcome a stability problem and 
sensitivity to outside contamination that is inherent to PCR-based 
detection systems, wherein the PNA probes bind to DNA with greater 
stability and selectivity compared to a complementary DNA sequence.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404. The prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the 
Technology Advancement Office, NIDDK, receives written evidence and 
argument that establishes that the grant of the license would not be 
consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    Properly filed competing applications for a license in response to 
this notice will be treated as objections to the contemplated license. 
Comments and objections submitted in response to this notice will not 
be made available for public inspection and, to the extent permitted by 
law, will not be released under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: February 10, 2016.
Anna Amar,
Acting Deputy Director, Technology Advancement Office, NIDDK.
[FR Doc. 2016-03187 Filed 2-16-16; 8:45 am]
BILLING CODE 4140-01-P